Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis

Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis

Background: A new goal in treatment of chronic myeloid leukemia (CML) in patients with stable deep molecular response (DMR) is maintaining durable treatment-free remission (TFR) after discontinuing tyrosine kinase inhibitor (TKI) treatment.Methods: We conducted a systematic review and meta-analysis...

Full description

Bibliographic Details
Main Authors:	Kang-kang Chen, Tai-feng Du, Pei-sheng Xiong, Guan-hua Fan, Wei Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-05-01
Series:	Frontiers in Oncology
Subjects:	tyrosine kinase inhibitors chronic myeloid leukemia treatment-free remission treatment discontinuation deep molecular response
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2019.00372/full

Similar Items

Evaluation of tyrosine kinase inhibitor discontinuation initiative in patients with chronic myeloid leukemia at princess noorah oncology center
by: Afnan Mohammed Noor, et al.
Published: (2022-01-01)

Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells
by: Yilin Chen, et al.
Published: (2021-10-01)

e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response
by: Sílvia Marcé, et al.
Published: (2024-01-01)

De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China
by: Jie Luo, et al.
Published: (2022-11-01)

Withdrawal syndrome after tyrosine kinase inhibitors discontinuation in patients with chronic myeloid leukemia
by: Ekaterina Yu. Chelysheva, et al.
Published: (2022-08-01)

Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors
by: Jee Hyun Kong, et al.
Published: (2020-05-01)

Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
by: Hiroshi Ureshino, et al.
Published: (2022-12-01)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
by: Matteo Molica, et al.
Published: (2020-09-01)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
by: Fang Cheng, et al.
Published: (2023-04-01)

Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study
by: Mehmet Özen, et al.
Published: (2017-02-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
by: Maria Dimou, et al.
Published: (2014-01-01)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
by: İbrahim C. Haznedaroğlu, et al.
Published: (2020-02-01)

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation
by: Matteo Dragani, et al.
Published: (2020-11-01)

Results of treatment of acute myeloid leukemia in central part of Iran
by: Farzaneh Ashrafi, et al.
Published: (2013-01-01)

Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission
by: Lorena Vigón, et al.
Published: (2020-12-01)

A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
by: Valentin García-Gutiérrez, et al.
Published: (2022-07-01)

In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy
by: María Belén Sanchez, et al.
Published: (2023-09-01)

Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation
by: Maria Cristina Puzzolo, et al.
Published: (2022-09-01)

Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey
by: Lou J, et al.
Published: (2018-06-01)

Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia
by: Yeojae Kim, et al.
Published: (2022-07-01)

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
by: A. Iurlo, et al.
Published: (2023-03-01)

Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review
by: Rinaldi I, et al.
Published: (2023-04-01)

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
by: Mario Annunziata, et al.
Published: (2020-06-01)

Treatment-free remission in patients with chronic myeloid leukemia: literature review
by: A. N. Petrova, et al.
Published: (2019-10-01)

Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy
by: A G Turkina, et al.
Published: (2017-12-01)

Front-Line Tyrosine Kinase Inhibitors in Pediatric Chronic Myeloid Leukemia: A Study on Efficacy and Safety
by: Jae Won Yoo, et al.
Published: (2023-07-01)

Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
by: Valentín García-Gutiérrez, et al.
Published: (2020-07-01)

Budget Impact analysis of the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) adult patients
by: Francesco Mennini, et al.
Published: (2017-07-01)

Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report
by: Isabella Capodanno, et al.
Published: (2021-06-01)

Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology
by: Vlad Moisoiu, et al.
Published: (2019-09-01)

Chronic myeloid leukaemia remission stability after tyrosine - kinase inhibitors therapy cessation: a review of literature
by: Nikolina Matić, et al.
Published: (2021-01-01)

Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
by: Massimo Breccia, et al.
Published: (2021-03-01)

FMS-like tyrosine kinase 3 internal tandem duplication mutation in patients with acute myeloid leukemia in Kurdistan region/Iraq
by: Sarween Sherzad Rasool, et al.
Published: (2023-01-01)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
by: Avital F. Barak, et al.
Published: (2011-12-01)

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia
by: Ehab Atallah, et al.
Published: (2018-04-01)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
by: Valentín García-Gutiérrez, et al.
Published: (2019-07-01)

A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia
by: Alicia Martín Roldán, et al.
Published: (2023-04-01)

Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients
by: Gabriel Etienne, et al.
Published: (2020-09-01)

Assessment of chronic myeloid leukemia patients' adherence with “tyrosine kinase inhibitors” in King Abdulaziz Medical City
by: Saad Saleh Aldughaythir, et al.
Published: (2017-01-01)

Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy
by: Petrushev B, et al.
Published: (2016-02-01)